Vascular Medicine News

Healio | Cardiology Today compiled a list of some of the most important news in cardiology from 2023.

The subset of patients with high-risk pulmonary embolism who had hemodynamic collapse had an in-hospital mortality rate of 42%, according to a retrospective analysis of a large registry.

In November, the FDA approved two renal denervation devices for people with uncontrolled hypertension despite maximally tolerated therapies. The approvals ushered in the first-ever interventional procedures with indications to lower BP.

Healio and Cardiology Today have compiled a list of the most-read news in cardiology in December 2023.

PHILADELPHIA — Two common reproductive health conditions, dysmenorrhea and polycystic ovary syndrome, are associated with increasing CVD risk in women, according to research presented at the American Heart Association Scientific Sessions.

Women with venous thromboembolism associated with pregnancy, the postpartum period or combined oral contraceptives who have finished primary short-term treatment may be considered for thrombophilia testing.

The AMA has adopted a policy in support of insurance coverage parity for evidence-based weight-loss medications “without exclusions or additional carve-outs,” the organization recently announced.

Researchers reported that exposure to elevated LDL and elevated systolic BP before age 55 years is associated with increased coronary heart disease risk independent of later-life BP and cholesterol levels.

Intravascular imaging-guided PCI showed benefit vs. angiography for patients with left main CAD, with significantly lower risk for cardiac death or spontaneous target vessel-related MI, researchers reported.

Promising new devices and emerging drug classes may improve BP control for some patients with difficult-to-treat hypertension, but clinicians must first address the structural inequities that impact access to care, according to a speaker.